MEI Pharma, Inc. (MEIP) News
Filter MEIP News Items
MEIP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MEIP News Highlights
- For MEIP, its 30 day story count is now at 2.
- Over the past 14 days, the trend for MEIP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG and MEI are the most mentioned tickers in articles about MEIP.
Latest MEIP News From Around the Web
Below are the latest news stories about MEI PHARMA INC that investors may wish to consider to help them evaluate MEIP as an investment opportunity.
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023SAN DIEGO, December 11, 2023--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced clinical data from the monotherapy dose escalation stage of the ongoing Phase 1 study evaluating voruciclib, a selective oral cyclin-dependent kinase 9 ("CDK9") inhibitor, alone and in combination with venetoclax (Venclexta®), a B-cell lymphoma 2 ("BCL2") inhibitor, in p |
11 Cheapest Stocks With Biggest UpsideIn this piece, we will take a look at the 11 cheapest stocks with the biggest upside. If you want to skip our introduction to stock valuation and recent market news, then take a look at 5 Cheapest Stocks With Biggest Upside. Identifying the right stocks to invest in is a science that involves evaluating […] |
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast CancerAstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer. |
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume RisesIronwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line. |
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational HighlightsSAN DIEGO, November 09, 2023--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the quarter ended September 30, 2023 and highlighted recent corporate events. |
Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View UpdatedAmicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates. The company tightens Galafold revenue guidance for 2023. |
MEI Pharma to Present at the Stifel 2023 Healthcare ConferenceSAN DIEGO, November 08, 2023--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will participate in the Stifel 2023 Healthcare Conference. David Urso, president and chief executive officer, will present a company overview and business update on Wednesday, November 15 at 8:35 AM Eastern Time. |
Axsome (AXSM) Q3 Loss Widens, Revenues Surpass EstimatesAxsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat estimates. The company's shares declined post earnings announcement. |
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common StockSAN DIEGO, November 06, 2023--MEI Pharma, Inc. (Nasdaq: MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that pursuant to the previously disclosed cooperation agreement with Anson Funds and Cable Car Capital, the Company’s Board of Directors today declared a special cash dividend (the "Dividend") of $1.75 per share of common stock, $0.00000002 par value, payable on December 6, 2023 to stockholders of record at the close |
Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales ViewCorcept's (CORT) third-quarter 2023 earnings and revenues surpass estimates. The company raises the full-year revenue guidance for 2023. |